CLINICAL TRIALS PROFILE FOR CATAPRES-TTS-1

All Clinical Trials for CATAPRES-TTS-1

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00223717 ↗	Treatment of Supine Hypertension in Autonomic Failure	Completed	Vanderbilt University	Phase 1	2001-01-01	Supine hypertension is a common problem that affects at least 50% of patients with primary autonomic failure. Supine hypertension can be severe, and complicates the treatment of orthostatic hypotension. Drugs used for the treatment of orthostatic hypotension (eg, fludrocortisone and pressor agents), worsen supine hypertension. High blood pressure may also cause target organ damage in this group of patients. The pathophysiologic mechanisms causing supine hypertension in patients with autonomic failure have not been defined. In a study, we, the investigators at Vanderbilt University, examined 64 patients with AF, 29 with pure autonomic failure (PAF) and 35 with multiple system atrophy (MSA). 66% of patients had supine systolic (systolic blood pressure [SBP] > 150 mmHg) or diastolic (diastolic blood pressure [DBP] > 90 mmHg) hypertension (average blood pressure [BP]: 179 ± 5/89 ± 3 mmHg in 21 PAF and 175 ± 5/92 ± 3 mmHg in 21 MSA patients). Plasma norepinephrine (92 ± 15 pg/mL) and plasma renin activity (0.3 ± 0.05 ng/mL per hour) were very low in a subset of patients with AF and supine hypertension. (Shannon et al., 1997). Our group has showed that a residual sympathetic function contributes to supine hypertension in patients with severe autonomic failure and that this effect is more prominent in patients with MSA than in those with PAF (Shannon et al., 2000). MSA patients had a marked depressor response to low infusion rates of trimethaphan, a ganglionic blocker; the response in PAF patients was more variable. At 1 mg/min, trimethaphan decreased supine SBP by 67 +/- 8 and 12 +/- 6 mmHg in MSA and PAF patients, respectively (P < 0.0001). MSA patients with supine hypertension also had greater SBP response to oral yohimbine, a central alpha2 receptor blocker, than PAF patients. Plasma norepinephrine decreased in both groups, but heart rate did not change in either group. This result suggests that residual sympathetic activity drives supine hypertension in MSA; in contrast, supine hypertension in PAF. It is hoped that from this study will emerge a complete picture of the supine hypertension of autonomic failure. Understanding the mechanism of this paradoxical hypertension in the setting of profound loss of sympathetic function will improve our approach to the treatment of hypertension in autonomic failure, and it could also contribute to our understanding of hypertension in general.
NCT00223717 ↗	Treatment of Supine Hypertension in Autonomic Failure	Completed	Vanderbilt University Medical Center	Phase 1	2001-01-01	Supine hypertension is a common problem that affects at least 50% of patients with primary autonomic failure. Supine hypertension can be severe, and complicates the treatment of orthostatic hypotension. Drugs used for the treatment of orthostatic hypotension (eg, fludrocortisone and pressor agents), worsen supine hypertension. High blood pressure may also cause target organ damage in this group of patients. The pathophysiologic mechanisms causing supine hypertension in patients with autonomic failure have not been defined. In a study, we, the investigators at Vanderbilt University, examined 64 patients with AF, 29 with pure autonomic failure (PAF) and 35 with multiple system atrophy (MSA). 66% of patients had supine systolic (systolic blood pressure [SBP] > 150 mmHg) or diastolic (diastolic blood pressure [DBP] > 90 mmHg) hypertension (average blood pressure [BP]: 179 ± 5/89 ± 3 mmHg in 21 PAF and 175 ± 5/92 ± 3 mmHg in 21 MSA patients). Plasma norepinephrine (92 ± 15 pg/mL) and plasma renin activity (0.3 ± 0.05 ng/mL per hour) were very low in a subset of patients with AF and supine hypertension. (Shannon et al., 1997). Our group has showed that a residual sympathetic function contributes to supine hypertension in patients with severe autonomic failure and that this effect is more prominent in patients with MSA than in those with PAF (Shannon et al., 2000). MSA patients had a marked depressor response to low infusion rates of trimethaphan, a ganglionic blocker; the response in PAF patients was more variable. At 1 mg/min, trimethaphan decreased supine SBP by 67 +/- 8 and 12 +/- 6 mmHg in MSA and PAF patients, respectively (P < 0.0001). MSA patients with supine hypertension also had greater SBP response to oral yohimbine, a central alpha2 receptor blocker, than PAF patients. Plasma norepinephrine decreased in both groups, but heart rate did not change in either group. This result suggests that residual sympathetic activity drives supine hypertension in MSA; in contrast, supine hypertension in PAF. It is hoped that from this study will emerge a complete picture of the supine hypertension of autonomic failure. Understanding the mechanism of this paradoxical hypertension in the setting of profound loss of sympathetic function will improve our approach to the treatment of hypertension in autonomic failure, and it could also contribute to our understanding of hypertension in general.
NCT00262470 ↗	Treatment of Orthostatic Intolerance	Active, not recruiting	National Institutes of Health (NIH)	Phase 1/Phase 2	1997-04-01	This trial is designed to study the effects of various mechanistically unique medications in controlling excessive increases in heart rate with standing and in improving the symptoms of orthostatic intolerance in patients with this disorder.
NCT00262470 ↗	Treatment of Orthostatic Intolerance	Active, not recruiting	Satish R. Raj	Phase 1/Phase 2	1997-04-01	This trial is designed to study the effects of various mechanistically unique medications in controlling excessive increases in heart rate with standing and in improving the symptoms of orthostatic intolerance in patients with this disorder.
NCT00329511 ↗	A Comparison of Compliance Between Clonidine Patch and Methyldopa for the Treatment of Chronic Hypertension in Pregnancy	Withdrawn	Afshan B. Hameed, M.D.	N/A	2004-09-01	High blood pressure (BP) before pregnancy is called chronic hypertension (CHTN), and is associated with an increased risk of development of pregnancy related high BP called preeclampsia, preterm delivery, decreased growth of the fetus, fetal death, premature separation of the placenta from the uterus resulting in damage to the fetus and cesarean delivery. Longer duration and severity of CHTN in pregnancy leads to worse outcomes for the mother and the fetus. Treatment of mild CHTN in pregnancy does not improve these outcomes, and therefore, medications to lower BP are used for moderate to severe hypertension. To date the literature on the medications used in pregnancy is extremely limited. Methyldopa is used as a first choice medicine for CHTN in pregnancy. It acts on the central nervous system (CNS) by relaxation of the blood vessels leading to a decrease in BP. It does not decrease the blood flow to the uterus, placenta, or the fetus (4). Methyldopa is a weak antihypertensive medicine given three or four times a day and frequently needs changes in the dose or may require an additional medication to control BP. This may lead to a greater chance of non compliance. Another option is Clonidine which is an effective antihypertensive treatment and is available in many forms (oral, parenteral, and transdermal.) It acts on the maternal CNS. Clonidine is not associated with teratogenic or neonatal side effects. Transdermal clonidine (catapres-TTS®) is a preparation of clonidine hydrochloride that can be released and absorbed transdermally over a 7-day period. The study will determine differences in compliance between the two antihypertensive regimens- oral methyldopa and Catapres-TTS, comparisons of patient tolerability, compliance and adequacy of BP control, as well as provide information on an alternate option for BP control.
NCT00329511 ↗	A Comparison of Compliance Between Clonidine Patch and Methyldopa for the Treatment of Chronic Hypertension in Pregnancy	Withdrawn	University of California, Irvine	N/A	2004-09-01	High blood pressure (BP) before pregnancy is called chronic hypertension (CHTN), and is associated with an increased risk of development of pregnancy related high BP called preeclampsia, preterm delivery, decreased growth of the fetus, fetal death, premature separation of the placenta from the uterus resulting in damage to the fetus and cesarean delivery. Longer duration and severity of CHTN in pregnancy leads to worse outcomes for the mother and the fetus. Treatment of mild CHTN in pregnancy does not improve these outcomes, and therefore, medications to lower BP are used for moderate to severe hypertension. To date the literature on the medications used in pregnancy is extremely limited. Methyldopa is used as a first choice medicine for CHTN in pregnancy. It acts on the central nervous system (CNS) by relaxation of the blood vessels leading to a decrease in BP. It does not decrease the blood flow to the uterus, placenta, or the fetus (4). Methyldopa is a weak antihypertensive medicine given three or four times a day and frequently needs changes in the dose or may require an additional medication to control BP. This may lead to a greater chance of non compliance. Another option is Clonidine which is an effective antihypertensive treatment and is available in many forms (oral, parenteral, and transdermal.) It acts on the maternal CNS. Clonidine is not associated with teratogenic or neonatal side effects. Transdermal clonidine (catapres-TTS®) is a preparation of clonidine hydrochloride that can be released and absorbed transdermally over a 7-day period. The study will determine differences in compliance between the two antihypertensive regimens- oral methyldopa and Catapres-TTS, comparisons of patient tolerability, compliance and adequacy of BP control, as well as provide information on an alternate option for BP control.

Clinical Trial Conditions for CATAPRES-TTS-1

Condition Name

Condition Name for CATAPRES-TTS-1
Intervention	Trials
Hypertension	3
Delirium	2
Fecal Incontinence	2
Opioid Related Disorders	1

Condition MeSH

Condition MeSH for CATAPRES-TTS-1
Intervention	Trials
Delirium	3
Hypertension	3
Fecal Incontinence	2
Pain, Postoperative	2

Clinical Trial Locations for CATAPRES-TTS-1

Trials by Country

Trials by Country for CATAPRES-TTS-1
Location	Trials
United States	11
United Kingdom	2
Netherlands	1
Brazil	1
Lithuania	1

Trials by US State

Trials by US State for CATAPRES-TTS-1
Location	Trials
Minnesota	3
Maryland	2
California	2
Tennessee	2
Pennsylvania	1

Clinical Trial Progress for CATAPRES-TTS-1

Clinical Trial Phase

Clinical Trial Phase for CATAPRES-TTS-1
Clinical Trial Phase	Trials
Phase 4	5
Phase 3	3
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for CATAPRES-TTS-1
Clinical Trial Phase	Trials
Completed	7
Terminated	3
Withdrawn	3

Clinical Trial Sponsors for CATAPRES-TTS-1

Sponsor Name

Sponsor Name for CATAPRES-TTS-1
Sponsor	Trials
Mayo Clinic	3
National Center for Research Resources (NCRR)	2
Edinburgh Napier University	1

Sponsor Type

Sponsor Type for CATAPRES-TTS-1
Sponsor	Trials
Other	36
NIH	5
Industry	4

CATAPRES-TTS-1 Market Analysis and Financial Projection

Last updated: May 3, 2026

CATAPRES-TTS-1 Clinical Trials Update, Market Analysis, and Projection

What is CATAPRES-TTS-1?

CATAPRES-TTS-1 is a transdermal delivery system for clonidine. The “TTS-1” strength corresponds to the 1 mg clonidine system used for hypertension and other labeled indications depending on jurisdiction. The brand name is commonly marketed in the US as Catapres-TTS (clonidine transdermal system). The product is an established, older therapy with an ongoing presence in formularies and chronic-care markets.

---

What clinical trials data exist for CATAPRES-TTS-1?

No current, active CATAPRES-TTS-1-specific Phase 2/3 registrational trials can be confirmed from the supplied dataset in this chat. This is consistent with the product profile of clonidine transdermal systems: mature, off-patent, and typically supported by older registrational literature and post-marketing pharmacovigilance rather than fresh large-scale confirmatory programs.

What is typically observable for an established transdermal clonidine product includes:

• Bioequivalence and comparative pharmacokinetic work tied to generics or line extensions (if any).
• Post-marketing safety monitoring and real-world utilization studies.
• Trials that are class-level (clonidine/transdermal delivery) rather than branded CATAPRES-TTS-1 by name.

Result: A branded CATAPRES-TTS-1 “clinical trials update” suitable for investment conclusions requires trial-line evidence (registrations, endpoints, enrollment, status) that is not present in the material available in this response.

---

What is the market context for transdermal clonidine (CATAPRES-TTS-1)?

Clonidine is a longstanding, low-cost cardiovascular agent. The transdermal format offers:

• Once-weekly dosing (clinical convenience lever versus multiple daily oral dosing).
• Avoidance of some first-pass metabolism, with a delivery profile designed for adherence.

Competitive landscape

• Generic clonidine transdermal systems typically drive pricing and volume.
• Therapeutic alternatives for hypertension include multiple classes with stronger contemporary guidance and market momentum, including ARBs, ACE inhibitors, CCBs, thiazides, and newer agents.
• Clonidine remains a practical option in specific patient subsets or when tolerability/adherence favors transdermal clonidine.

Demand drivers

• Chronic hypertension management is steady, but brand share depends on payer preferences and generic penetration.
• Transdermal delivery supports adherence and can reduce missed doses for some populations.
• Clonidine also has additional off-label and specialty uses in practice in some markets, but payer coverage for off-label uses is variable.

Supply and pricing

• Because the active ingredient is mature and generics exist, brand pricing power is limited.
• Growth is typically driven by volume retention and substitution dynamics rather than category expansion.

---

How is CATAPRES-TTS-1 projected to perform?

Without confirmed CATAPRES-TTS-1-specific pipeline assets, trial milestones, or branded lifecycle catalysts, forward projections must be framed as mature product economics. The most defensible forecast structure for a mature branded transdermal clonidine product is:

Base case: steady-to-declining brand share

• Category demand stays relatively stable due to chronic disease prevalence.
• Brand share erodes under generic substitution and formulary switches.
• Revenue is dominated by price and distribution channel dynamics, with modest net change unless supply disruptions or payer shifts occur.

Bull case: durable formulary placement

• Maintains niche positioning where transdermal clonidine is preferred or where switches are restricted by formulary logic.
• Could benefit from adherence-focused prescribing and institutional protocols.

Bear case: continued generic substitution

• Ongoing payer-driven generic ordering pulls demand away from the brand.
• Any reduction in brand inventory allocation or contracting friction accelerates share loss.

Result: The projection for CATAPRES-TTS-1 is best treated as a mature-brand, low-innovation profile where upside is constrained and downside is share erosion.

---

What matters most for near-term strategy and valuation?

For a mature transdermal clonidine brand, decision-grade drivers are not Phase 3 readouts. They are contract and channel mechanics:

• Formulary status (preferred tier vs non-preferred).
• Wholesale acquisition cost and rebate structure relative to generics.
• State Medicaid and large payer policies for transdermal clonidine products.
• Switch programs triggered by pharmacy and medical benefit alignment.
• Discontinuation risk of branded product supply or package configurations.

---

Key Takeaways

• CATAPRES-TTS-1 is a clonidine transdermal system with a mature lifecycle and limited visibility of branded, registration-grade clinical trial activity in current data conditions.
• Market growth is constrained by generic competition and the broader availability of multiple first-line hypertension classes.
• Projections are share-and-contract driven, with the most likely trajectory being steady-to-declining branded share absent a new clinical or regulatory catalyst.

---

FAQs

1. Is CATAPRES-TTS-1 a new drug innovation?
   No. It is a mature clonidine transdermal product with established use patterns.

2. Will clinical trial updates be a primary driver of CATAPRES-TTS-1 market performance?
   No. Market outcomes for this type of mature branded product are primarily driven by payer contracting, formulary positioning, and generic substitution.

3. What is the main competitive pressure for CATAPRES-TTS-1?
   Generic clonidine transdermal products and payer preferences for lower-cost options.

4. What dosing convenience does the transdermal format provide?
   Transdermal delivery supports reduced dosing frequency versus many oral regimens, which can improve adherence for some patients.

5. What is the most plausible revenue trajectory?
   A mature, likely share erosion profile unless the brand maintains strong formulary placement and contracting economics.

---

References

[1] FDA. Drugs@FDA: Catapres-TTS (clonidine transdermal system). https://www.accessdata.fda.gov/scripts/cder/daf/
[2] DailyMed. Catapres-TTS-1 (clonidine transdermal system) prescribing information. https://dailymed.nlm.nih.gov/
[3] U.S. National Library of Medicine. ClinicalTrials.gov. https://clinicaltrials.gov/